Multi-Pathway Study for Oxaliplatin Resistance Reduction [PDF]
Current Issues in Molecular BiologyChemotherapy for cancer frequently uses platinum-based medications, including oxaliplatin, carboplatin, and cisplatin; however, due to their high systemic toxicity, lack of selectivity, drug resistance, and other side effects, platinum-based medications ...
Tong Ye +4 more
doaj +6 more sources
Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2 [PDF]
Molecular Therapy: Oncolytics, 2021 Although oxaliplatin is an effective chemotherapeutic drug commonly used for colorectal cancer (CRC) treatment, drug resistance usually occurs during the long-term use of it.
Wei Sun +4 more
doaj +3 more sources
Exploration, 2023 Oxaliplatin is a first‐line chemotherapy drug widely adopted in colorectal cancer (CRC) treatment. However, a large proportion of patients tend to become resistant to oxaliplatin, causing chemotherapy to fail.
Peilong Li +12 more
doaj +2 more sources
Targeting FBXL5 to induce ferroptosis and reverse oxaliplatin resistance in iron-rich colorectal cancer [PDF]
Scientific ReportsOxaliplatin resistance remains a major challenge in colorectal cancer (CRC) treatment. We investigated the FBXL5/IREB2/TFRC axis in ferroptosis-mediated resistance reversal.
Miaomiao Wang +7 more
doaj +2 more sources
UBAP2L-driven stress granule formation links oxaliplatin resistance to gastric cancer [PDF]
Communications BiologyStress granules (SGs), which are phase-separating organelles that serve as protective cellular mechanisms in response to various harmful stimuli, have an unclear role in oxaliplatin resistance.
Chaorui Wu +12 more
doaj +2 more sources
Influence of Citrobacter freundii on NINJ2 Expression and Oxaliplatin Resistance in Colorectal Cancer [PDF]
Cancer MedicineBackground Oxaliplatin, a third‐generation platinum‐based chemotherapeutic agent, is widely used in the treatment of colorectal cancer (CRC). However, some patients do not respond effectively to oxaliplatin, and intrinsic resistance to the drug poses a ...
Reio Ueta +5 more
doaj +2 more sources
PUM2 inhibits ferroptosis and enhances oxaliplatin resistance in COAD via the NEDD4L/NRF2 axis [PDF]
Translational OncologyOxaliplatin resistance remains a significant therapeutic challenge in the treatment of colon adenocarcinoma (COAD). In this study, we identified the RNA-binding protein PUM2 as a key driver of oxaliplatin resistance. Bioinformatics analysis revealed that
Jiacheng Xie +5 more
doaj +2 more sources
Advanced Science, 2023 Oxaliplatin is a widely used chemotherapy drug for patients with advanced colorectal cancer (CRC); however, frequent drug resistance limits its therapeutic efficacy in patients.
Kaixuan Zeng +7 more
doaj +2 more sources
The Role and Mechanism of Innate Immune Regulation in Overcoming Oxaliplatin Resistance and Enhancing Anti-Tumor Efficacy in Colorectal Cancer [PDF]
PharmaceuticalsBackground/Objectives: The reversal effect of cGAMP, as a STING pathway regulator, on oxaliplatin resistance in colorectal cancer was investigated, and its mechanism was proposed.
Xiaoqing Wang +3 more
doaj +2 more sources
Targeting the NSUN2-DHODH axis reverses ferroptosis resistance and oxaliplatin resistance in colorectal cancer. [PDF]
Front PharmacolBackground Oxaliplatin (OXA) is a standard chemotherapy for advanced colorectal cancer (CRC), yet acquired resistance frequently limits its efficacy. Ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation, has emerged as a promising strategy to overcome chemoresistance.
Zhang J +10 more
europepmc +4 more sources